• Niranjan

Cyclops Medtech receives funding

Updated: Dec 4, 2018


With USD $1million investment from Unitus Ventures and others, plans to expand to 1,500 installations over next 5 years


We are happy to share that Cyclops Medtech has successfully raised USD 1 Million in funding from Unitus Ventures as well as angel investor Mr. C P Bothra. This funding will help us further augment our leadership position in the neuro vestibular diagnosis space and also launch few other products for neuro vestibular diagnosis and rehabilitation.


Using eye tracking technology, Cyclops Medtech’s BalanceEye product has made diagnosis of various neuro-vestibular conditions easy and accurate and reduced the price to a fraction of that of existing imaging technologies. Dizziness and other symptoms of multiple neuro-vestibular disorders (including vertigo, migraine and balance) manifest in the pupil movement. Cyclops’ platform captures, measures and analyses these manifestations, helping clinicians determine their root cause in order to plan appropriate early stage treatment.


Prior to the launch of Cyclops’ product BalanceEye, India had very few dizziness and balance assessment platforms and most were located in metros or tier 1 cities. Having achieved 100 installations in a short span of 16 months, Cyclops is changing that statistic. The company is a market leader in its space with close to 62% of the market share. Moreover, Cyclops is significantly increasing access to diagnosis and timely treatment for the masses as well as reducing patients’ out-of-pocket expenses. BalanceEye’s scale-up is largely concentrated in tier 2, 3 and 4 cities including towns such as Morbi, Miraj, Islampur, Madurai, Trichy, Bargarh and Shillong.  The product also has the ability to offer remote diagnosis, which augments clinical care in regions where physician availability is sparse and expands clinical reach.


In the last 16 months more than 10,000 tests have been performed on BalanceEye platform and many alarming medical conditions like Midbrain infarct, cerebellar vermis atrophy, frontal meningioma, neurovascular cross compression, etc. have been detected. Many of these patients come from rural hinterlands of India.” says, Dr. Srinivas Dorasala, Co-founder, Cyclops Medtech.

Eye tracking based diagnostic solutions are portable, affordable, accurate and non-invasive

“Eyes are windows to a patient’s neuro-vestibular world. Pupil based diagnosis is portable, affordable, accurate and completely non invasive. It helps millions of people in emerging economies to access cutting edge diagnosis at the right time and right cost. We intend to use funds from this round to further augment our leadership position by rapidly increasing the installation as well as subscription base in India as well as few other emerging markets. By achieving the milestone of 100 installations, we already have the highest base in India. We would also fast-track development of our stroke screening product and launch it next year.” said Mr. Niranjan Subbarao, Co-founder, Cyclops Medtech.

“We met Cyclops Medtech through LetsVenture and were impressed with their vision of transforming balance disorder diagnosis through affordable and easily accessible technologies.

What attracted us the most to Cyclops’ was its ability to maintain a low price for its product while providing easy to use cutting edge technology, making the solution relevant to both developed and developing markets.

This aligned with our mission to support innovative healthcare businesses that have intrinsic capability to create a significant social impact.”, said Milind Shah, Partner at Unitus Ventures.

“We are very bullish on low cost medical devices being built out of India, and have seen a spike in the demand for such startups by investors. Cyclops uniquely applies machine learning on top of eye movement data collected by their hardware to predict diseases like vertigo, and can have immense impact in developing countries. Having done 150 deals with angel investors in the last 4 years, we started working actively with institutional investors in 2018. We now work with over 60 institutional funds from India and Singapore and are glad to have our first closure with Unitus Ventures.” said Shanti Mohan, Founder and CEO at LetsVenture.

Way Forward: Rapidly scale up product installations in India and neighbouring  markets

In the coming years, Cyclops Medtech plans to to scale up BalanceEye installations across India, primarily in tier 2 and tier 3 cities. In addition, the company will also focus on capturing other markets in Asia with a target of 1,000 installations over the next 5 years. Other than BalanceEye, the company is also working on 3 other products in the neuro-vestibular space.


0 views

© 2015 Cyclops Medtech Private Limited